Item 1.01. Entry into a Material Definitive Agreement.

Business Combination Agreement

On June 21, 2021, Thimble Point Acquisition Corp., a Delaware corporation ("THMA"), entered into a Business Combination Agreement (the "Business Combination Agreement") with Oz Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of THMA ("Merger Sub"), and Pear Therapeutics, Inc., a Delaware corporation ("Pear"), pursuant to which Merger Sub will merge with and into Pear, with Pear surviving the merger as a wholly-owned subsidiary of THMA (the "Merger").

Merger Consideration

Upon the terms and subject to the conditions set forth in the Business Combination Agreement, at the effective time of the Merger (the "Effective Time"):





    (i)  Each share of Pear's common stock, par value $0.0001 per share (the "Pear
         Common Shares"), issued and outstanding as of immediately prior to the
         Effective Time (excluding shares owned by Pear as treasury stock or
         dissenting shares) will be cancelled and converted into (x) the right to
         receive the Per Share Upfront Consideration (as defined below) and
         (y) the contingent right to receive Earn Out Shares described under "Earn
         Out Consideration" below (with respect to each Pear Common Share,
         collectively, the "Per Share Consideration" and with respect to all Pear
         Common Shares and Pear Preferred Shares (as defined below), in the
         aggregate, the "Merger Consideration"). The "Per Share Upfront
         Consideration" is equal to such number of THMA's Class A common stock,
         par value $0.0001 per share (the "THMA Class A Shares") equal to (i)
         $1,200,000,000 divided by $10.00 divided by (ii) the total number of Pear
         Common Shares outstanding immediately prior to the Effective Time,
         expressed on an as-exercised and as-converted to Pear Common Shares basis
         (including any Pear Common Shares underlying Pear Vested In-the-Money
         Options (on a net exercise basis) or Pear Preferred Shares) (the "Pear
         Outstanding Shares").




    (ii) Each share of Pear's preferred stock, par value $0.0001 per share (the
         "Pear Preferred Shares"), issued and outstanding as of immediately prior
         to the Effective Time will be cancelled and converted into the right to
         receive Per Share Consideration in respect of such number of Pear Common
         Shares as set forth on the Consideration Schedule (as defined below).




    (iii) Each Pear Option that is unexercised and outstanding as of immediately
          prior to the Effective Time and that has a per share exercise price less
          than the Per Share Upfront Consideration multiplied by $10.00 (a "Pear
          In-the-Money Option") will be cancelled in exchange for an option to
          purchase a number of THMA Class A Shares as set forth on the
          Consideration Schedule at an exercise price as set forth on such
          Consideration Schedule.




    (iv) Each warrant to purchase Pear Common Shares ("Pear Warrant") will be
         converted into a warrant to acquire a number of THMA Class A Shares in an
         amount and at an exercise price and subject to such terms and conditions,
         in each case, as set forth on the Consideration Schedule. Subject to
         certain exceptions, such terms and conditions will be the same terms and
         conditions as were applicable to the Pear Warrant immediately prior to
         the Effective Time.

The "Consideration Schedule" sets forth (a) the portion of the Merger Consideration to which a holder of Pear Common Shares or Pear Preferred Shares, as applicable, would be entitled to receive on a proportionate, as-converted basis under Pear's certificate of incorporation and bylaws, each as amended or supplemented as of the Effective Time, and (b) with respect to the conversion of Pear In-the-Money Options to options to purchase THMA Class A Shares, such equitable adjustments to the number of shares and the exercise price to reflect the Merger and the price per THMA Class A Share.

Pursuant to the terms of the Business Combination Agreement, THMA is required to cause the THMA Class A Shares to be issued in connection with the transactions contemplated by the Business Combination Agreement (the "Transactions") to be listed on the NASDAQ Capital Market ("Nasdaq") prior to the closing of the Merger (the "Closing" and the date on which the Closing occurs, the "Closing Date").

--------------------------------------------------------------------------------

Earn Out Consideration

Subject to certain exceptions, during the period between the date that is 90 days following the Closing and the fifth anniversary of the Closing (the "Earn Out Period"), THMA will issue to eligible Pear stockholders up to 12,395,625 additional THMA Class A Shares in the aggregate (the "Earn Out Shares") in three equal tranches of 4,131,875 Earn Out Shares, respectively, upon THMA achieving $12.50, $15.00 or $17.50, respectively, as its volume weighted average price per share for any 20 trading days within a 30 consecutive trading day period (as adjusted for stock splits, reverse stock splits, stock dividends, reorganizations, recapitalizations, reclassifications, combination, exchange of shares or the like).

Representations and Warranties

The Business Combination Agreement contains customary representations and warranties of the parties thereto with respect to, among other things, (a) organization and qualification, (b) capital structure, (c) authorization to enter into the Business Combination Agreement, (d) approvals and permits, (e) financial statements, (f) absence of changes, (g) absence of undisclosed liabilities, (h) litigation, (i) employee matters, (j) compliance with laws, . . .

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an


           Off-Balance Sheet Arrangement of a Registrant.


On June 21, 2021, THMA issued an unsecured promissory note (the "Note") in the principal amount of $1,000,000 to the Sponsor. The Note does not bear interest and is repayable in full upon consummation of THMA's initial business combination (an "Initial Business Combination"). If THMA does not complete an Initial Business Combination, the Note shall not be repaid and all amounts owed under it will be forgiven. Upon the consummation of an Initial Business Combination, the Sponsor shall have the option, but not the obligation, to convert the principal balance of the Note, in whole or in part, to warrants of THMA, at a price of $1.50 per warrant (the "Warrants"). The terms of the Warrants will be identical to the terms of the warrants issued by THMA to the Sponsor in a private placement that took place simultaneously with the THMA's initial public offering. The Note is subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the Note and all other sums payable with regard to the Note becoming immediately due and payable.

The Note was issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

The foregoing description of the Note does not purport to be complete and is qualified in its entirety by reference to the full text of the Note, a copy of which is attached as Exhibit 10.7 hereto, and the terms of which are incorporated herein by reference.

Item 3.02. Unregistered Sales of Equity Securities.

The information set forth above in Item 2.03 of this Report and in Item 1.01 of this Report under the headings "Subscription Agreements" and "Forward Purchase Agreement Amendment" is incorporated by reference herein. The THMA Class A Shares to be issued in connection with the Subscriptions and Forward Purchase will not be registered under the Securities Act, and the offers and sales of securities with respect thereto were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.

--------------------------------------------------------------------------------

Item 7.01. Regulation FD Disclosure.

On June 22, 2021, THMA and Pear issued a press release announcing their entry into the Business Combination Agreement. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Furnished as Exhibits 99.2 and 99.3 hereto and incorporated into this Item 7.01 by reference are the investor presentation and subsequent investor presentation supplement, respectively, that THMA and Pear have prepared for use in connection with the announcement of the Merger. Furnished herewith as Exhibit 99.4 and 99.5 hereto and incorporated into this Item 7.01 by reference are the conference call presentation and the transcript of a pre-recorded joint conference call held on June 22, 2021, by THMA and Pear in connection with the announcement of their entry into the Business Combination Agreement.

The foregoing (including Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.

IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT

This Current Report on Form 8-K relates to a proposed transaction between Pear and THMA and does not constitute an offer to sell or exchange any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This Current Report on Form 8-K may be deemed to be solicitation material in respect of the proposed transactions contemplated by the Business Combination Agreement. In connection with such proposed transactions, THMA intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will include a proxy statement of THMA and a prospectus of THMA. STOCKHOLDERS OF THMA AND PEAR ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THMA'S PROXY STATEMENT AND PROSPECTUS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SUCH PROPOSED TRANSACTIONS. Investors and security holders will be able to obtain the documents free of charge at the SEC's web site, http://www.sec.gov, and THMA stockholders will receive information at an appropriate time on how to obtain transaction-related documents free of charge from THMA. Such documents are not currently available.

PARTICIPANTS IN SOLICITATION

THMA and Pear and their respective directors and officers may be deemed to be participants in the solicitation of proxies from THMA's stockholders in respect of the proposed transactions. Information about THMA's directors and executive officers and their ownership of THMA's securities is set forth in THMA's filings with the SEC, including THMA's Registration Statement on Form S-1, which was declared effective by the SEC on February 1, 2021. To the extent that holdings of THMA's securities have changed since the amounts printed in THMA's Registration Statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

FORWARD-LOOKING STATEMENTS

Certain statements, estimates, targets and projections in this Current Report on Form 8-K may be considered forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between THMA and Pear. Forward-looking statements generally relate to future events involving, or future performance of, THMA or Pear. For example, projections of future EBITDA, statements regarding anticipated growth in the industry in which Pear operates and anticipated growth in demand for Pear's products, projections of Pear's future financial results and other metrics, the satisfaction of closing conditions to the Merger and the timing of the completion of the Merger are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

--------------------------------------------------------------------------------

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by THMA and its management, and Pear and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the risk that the Merger, including the contemporaneous private placement of equity securities (the "PIPE investment"), may not be completed in a timely manner or at all, which may adversely affect the price of THMA's securities; (ii) the risk that the Merger may not be completed by THMA's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by THMA; (iii) the lack of a third party valuation in determining whether or not to pursue the Merger; (iv) the amount of the costs, fees, expenses and other charges related to the Merger and PIPE investment; (v) the outcome of any legal proceedings that may be instituted against THMA, Pear, the combined company or others following the announcement of the Business Combination Agreement, the ancillary agreements contemplated thereby and the transactions contemplated thereby (including the Merger); (vi) the inability to complete the Merger due to the failure to obtain approval of the stockholders of THMA, or Pear to obtain financing to complete the Merger or to satisfy other conditions to closing; (vii) changes to the proposed structure of the Merger that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Merger; (viii) the ability to meet stock exchange listing standards following the consummation of the Merger; (ix) the risk that the Merger disrupts current plans and operations of Pear or diverts management's attention from Pear's ongoing business operations and potential difficulties in Pear employee retention as a result of the announcement and consummation of the Merger; (x) the ability to recognize the anticipated benefits of the Merger, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (xi) costs related to the Merger; (xii) changes in applicable laws or regulations; (xiii) the possibility that Pear or the combined company may be adversely affected by other economic, business, regulatory, and/or competitive factors; (xiv) Pear's estimates of expenses and profitability; (xv) the evolution of the markets in which Pear competes; (xvi) the ability of Pear to implement its strategic initiatives and continue to innovate its existing products; (xvii) the ability of Pear to defend its intellectual property and satisfy regulatory requirements; (xviii) the ability of THMA to issue equity or equity-linked securities in connection with the Merger or in the future; (xix) the impact of the COVID-19 pandemic on Pear's business; and (xx) other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in THMA's final prospectus dated February 1, 2021 relating to its initial public offering and other risks and uncertainties indicated from time to time in the definitive proxy statement to be delivered to THMA's stockholders and related registration statement on Form S-4, including those set forth under "Risk Factors" therein, and other documents filed or to be filed with the SEC by THMA. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and THMA and Pear assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither THMA nor Pear gives any assurance that either THMA or Pear will achieve its expectations. The inclusion of any statement in this communication does not constitute an admission by THMA or Pear or any other person that the events or circumstances described in such statement are material.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits:



Exhibit     Description

 2.1*         Business Combination Agreement, dated as of June 21, 2021, by and
            among Thimble Point Acquisition Corp., Oz Merger Sub Inc. and Pear
            Therapeutics, Inc.

10.1*         Sponsor Support Agreement, dated as of June 21, 2021, by and among
            LJ10 LLC, Thimble Point Acquisition Corp., Pear Therapeutics, Inc. and
            certain other parties thereto.

10.2*         Form of Company Stockholder Support Agreement by and among Thimble
            Point Acquisition Corp., Pear Therapeutics, Inc. and the stockholder
            of Pear Therapeutics, Inc. identified on the signature page thereto.


10.3          Form of Stockholder Lock-Up Agreement by and among Thimble Point
            Acquisition Corp., Pear Therapeutics, Inc. and the stockholder of Pear
            Therapeutics, Inc. identified on the signature page thereto.

--------------------------------------------------------------------------------


10.4       Form of Subscription Agreement by and among Thimble Point Acquisition
         Corp., Pear Therapeutics, Inc. and the investor identified on the
         signature page thereto.

10.5*      Form of Registration Rights Agreement by and among Pear Holdings Corp.,
         LJ10 LLC, KLP SPAC 1 LLC, certain other stockholders of Thimble Point
         Acquisition Corp and certain former stockholders of Pear Therapeutics,
         Inc.

10.6       First Amendment to Forward Purchase Agreement, dated as of June 21,
         2021, by and among Thimble Point Acquisition Corp. and KLP SPAC 1 LLC.

10.7       Promissory Note, dated June 21, 2021, issued by Thimble Point
         Acquisition Corp. to LJ10 LLC.

99.1       Press Release issued by THMA and Pear on June 22, 2021.

99.2       Investor Presentation, dated May 2021.

99.3       Investor Presentation Supplement, dated June 2021.

99.4       Transcript for Joint Investor Call, dated June 22, 2021.

99.5       Presentation for Joint Investor Call



* Certain exhibits and schedules to this Exhibit have been omitted in accordance

with Regulation S-K Item 601(b)(2). THMA agrees to furnish supplementally a

copy of all omitted exhibits and schedules to the Securities and Exchange

Commission upon its request.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses